Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Vodicka P, Benesova K, Janikova A, Prochazka V, Belada D, Mocikova H, Steinerova K, Duras J, Karban J, Hanackova V, Sykorova A, Obr A, Trneny M. Vodicka P, et al. Among authors: duras j. Eur J Haematol. 2022 Aug;109(2):162-165. doi: 10.1111/ejh.13784. Epub 2022 May 11. Eur J Haematol. 2022. PMID: 35502609 Clinical Trial.
Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M. Janikova A, et al. Among authors: duras j. Leuk Lymphoma. 2015;56(8):2350-6. doi: 10.3109/10428194.2014.990010. Epub 2015 Jan 21. Leuk Lymphoma. 2015. PMID: 25426666
Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M. Janikova A, et al. Among authors: duras j. Leuk Lymphoma. 2016 May;57(5):1094-103. doi: 10.3109/10428194.2015.1079313. Epub 2015 Oct 12. Leuk Lymphoma. 2016. PMID: 26293000
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova M, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M. Janikova A, et al. Among authors: duras j. Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9. Ann Hematol. 2018. PMID: 29318369
The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.
Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, Sykorova A, Klener P, Benesova K, Pirnos J, Duras J, Mocikova H, Trneny M. Belada D, et al. Among authors: duras j. Leuk Res. 2018 Oct;73:29-38. doi: 10.1016/j.leukres.2018.08.019. Epub 2018 Aug 31. Leuk Res. 2018. PMID: 30195062
Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia.
Král Z, Michalka J, Móciková H, Marková J, Sýkorová A, Belada D, Jungová A, Vokurka S, Lukášová M, Procházka V, Ďuraš J, Hájek R, Dušek L, Drgoňa Ľ, Ladická M, Ballová V, Vranovský A. Král Z, et al. Among authors: duras j. J Cancer. 2019 Aug 28;10(21):5041-5048. doi: 10.7150/jca.29308. eCollection 2019. J Cancer. 2019. PMID: 31602255 Free PMC article.
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).
Janikova A, Michalka J, Bortlicek Z, Chloupkova R, Campr V, Kopalova N, Klener P, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Trneny M. Janikova A, et al. Among authors: duras j. Ann Hematol. 2020 Jul;99(7):1583-1594. doi: 10.1007/s00277-020-04099-y. Epub 2020 Jun 6. Ann Hematol. 2020. PMID: 32506244
Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL).
Janikova A, Michalka J, Chloupkova R, Kopalova N, Campr V, Kamaradova K, Kren L, Belada D, Benesova K, Dlouha J, Klener P, Procházka V, Mocikova H, Duras J, Trneny M. Janikova A, et al. Among authors: duras j. Ann Hematol. 2022 Apr;101(4):789-798. doi: 10.1007/s00277-022-04759-1. Epub 2022 Jan 21. Ann Hematol. 2022. PMID: 35061088
22 results